Prostate cancer recurrence after surgery is nearly double in smokers
the ONA take:
New research points out another cancer prognosis worsened by smoking. This research from an international group of scientists and clinicians from the United States and Europe found that current smokers and those who quit less than 10 years previously are at higher risk of prostate cancer recurrence after surgery.
The group retrospectively reviewed biochemical prostate cancer recurrence in 7,191 men who had undergone radical prostatectomy.
Among the men, approximately one-third each were never smokers, former smokers, and current smokers. After a median follow-up of 28 months, current smokers had approximately double the chance of the cancer recurring. Those who had quit within the last 10 years had a significantly higher risk.
The researchers report that their results confirm what is seen in many other cancers: smoking increases the risk of recurrence after initial treatment.
Furthermore, they recommend that patients stop smoking after a diagnosis of prostate cancer is determined.
Current smokers and those who quit less than 10 years previously are at higher risk of prostate cancer recurrence after surgery.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|